

## Treatment of Laboratory Animals

Maurice B. Visscher's article (28 May, p. 916) on the Animal Welfare Act of 1970 (P.L. 91-579) leaves the scientific investigator with an unjustified sense of security that there is under this act no possibility of bureaucratic interference with the design or execution of any experiment.

It is true that Section 13 of P.L. 91-579 contains language to the effect that nothing preceding Section 13 can be construed as authorizing the Secretary of Agriculture to promulgate rules, regulations, or orders with regard to design, outlines, guidelines, or performance of actual research or experimentation by a research facility. Immediately following, however, is what is known in governmental circles as a "march-in clause":


Provided, however, that the Secretary shall require at least annually, every research facility to show that professionally acceptable standards governing care, treatment and use of animals including appropriate use of anesthetic, analgesic and tranquilizing drugs during experimentation are being followed by the research facility during actual research or experimentation.

This clause will certainly leave the investigator or facility open to question if some functionary of the Department of Agriculture assigned to reading these annual reports does not interpret "professionally acceptable standards" as the investigator or research facility does. These standards have yet to be decided upon, and even when that occurs they may not conform to the investigator's ideas of professionally acceptable standards.

Because of the quoted clause, the American Society For Pharmacology and Experimental Therapeutics did not endorse the legislation which became P.L. 91-579. Rather, the society consistently and publicly, on the recommendation of its Committee on Public Affairs, endorsed the legislation with regard to treatment of laboratory animals proposed by Representative Paul G. Rogers (D-Fla.) and Senator Jacob K. Javits (R-N.Y.) in the 90th and 91st Congress (1966-1970). We still believe that the Rogers-Javits proposals would have better served the interests of all concerned.

LEONARD PROCITA  
*Committee on Public Affairs,  
American Society For Pharmacology  
and Experimental Therapeutics,  
Albany Medical College,  
Albany, New York 12208*

12 NOVEMBER 1971



## the technology that separates tumorogens from antigens in vaccines

Some viral vaccines have caused tumors in mice so pharmaceutical manufacturers, of course, have to eliminate the tumorigenic agents with extreme prejudice before the vaccines can be shot into men.

One way to do it is to bust up the virus into antigenic pieces with chemicals. In doing this, though, viral DNA, which can be tumorigenic, is let loose. Since antigen molecules and DNA molecules can't easily be separated on the basis of size, the chemical solution becomes part of the problem.


That part of the problem can be solved by breaking up DNA into pieces too small to carry genetic information with DNase; but this enzyme also acts as an antigen and a vaccine with two different antigens hardly meets acceptable standards of biological purity. So there's a whole new problem.

But happily, DNase can be neatly removed by Millipore ultrafiltration. Our Pellicon membrane (molecular weight limit: 100,000) retains the viral antigens (MW: 300,000) while the DNase (MW: 50,000) is washed through by a buffer solution.

Pellicon (thin skin) membranes are ideal for this job because they adsorb almost none of the molecules being separated (at the same time, they absorb a lot of handling because the thin skin is supported by a porous substrate). Other advantages: Pellicon membranes can be sterilized; they are shipped dry; and can be installed dry in pressure

cells (easier to handle than some others which, we hear, have to be kept wet or packed with foreign stabilizers to preserve their integrity).

For those who might want all this happiness in a 1,000 MW membrane, we have that, too. Plus systems for processing from a few ml to several liters, complete with cells, pressure tanks, et cetera.



We'll be glad to consult on applications and perhaps even break security and tell about our new high volume ultrafiltration systems (higher than laboratory and pilot scale) which are due for unveiling soon. For detailed information on Millipore ultrafiltration systems, write or use the reader service card. For immediate service, dial 800-225-1380 (toll-free).

For ultrafiltration information, Circle No. 33 on Readers' Service Card

## .. can solve many fluid quality problems.

A wide variety of Millipore tools and techniques are available for making precision separations in laboratory and industrial process fluids. To receive a brochure outlining the scope of the technology, write, or use the reader service card, Millipore Corporation, Bedford, Massachusetts 01730.

For technology brochure, Circle No. 34 on Readers' Service Card